According to filings with the U.S. Securities and Exchange Commission, GENEOS Therapeutics is raising $9,999,996.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Niranjan Sardesai played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GENEOS Therapeutics
At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer your bodys own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies. Geneos’ clinical results do not come by accident. The data validate the importance of the company’s multi-year effort to optimize each and every aspect of the process of vaccination to treat cancer. These proprietary and IP protected innovations have been integrated into its GT-EPIC™ platform for the development of uniquely personalized immunotherapies for cancer. GT-EPIC results from a holistic and ground up approach to addressing all of the opportunities and challenges of personalized therapeutic cancer vaccination and confers many therapeutic advantages embedded within our PTCVs.

To learn more about GENEOS Therapeutics, visit http://geneostx.com/

Contact:
Niranjan Sardesai, President and Chief Executive Officer
267-440-4232
https://www.linkedin.com/in/niranjan-sardesai-7645131/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.